Skip to main content
. Author manuscript; available in PMC: 2015 Jun 8.
Published in final edited form as: Gynecol Oncol. 2012 Sep 14;127(3):451–455. doi: 10.1016/j.ygyno.2012.09.008

Fig. 1.

Fig. 1

Kaplan–Meier progression free and overall survival curves for 35 eligible, relapsed cervix cancer patients treated with a weekly dosing schedule with nab-paclitaxel. Median progression-free survival was 5.0 months, while median overall survival was 9.4 months.